Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05077709
Title	IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC
Recruitment	Active, not recruiting
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	IO Biotech
Indications	head and neck squamous cell carcinoma urethra transitional cell carcinoma ureter transitional cell carcinoma lung non-small cell carcinoma bladder urothelial carcinoma renal pelvis transitional cell carcinoma
Therapies	IO102-IO103 + Pembrolizumab
Age Groups:	senior \| adult
Covered Countries	USA \| GBR \| ESP